Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Avrobio Inc (NQ: AVRO )

14.39 USD -0.55 (-3.68%)
Official Closing Price Updated: 4:23 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Avrobio Inc

< Previous 1 2 3 Next >
AVROBIO to Present at the ICR Conference 2021
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO,... 
From Business Wire News Releases
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory... 
From Business Wire News Releases
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a... 
From Business Wire News Releases
AVROBIO Announces Closing of Underwritten Public Offering
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common... 
From Business Wire News Releases
AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering... 
From Business Wire News Releases
AVROBIO Announces Proposed Public Offering of Common Stock
AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in... 
From Business Wire News Releases
AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced positive new data across its clinical... 
From Business Wire News Releases
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory... 
From Business Wire News Releases
AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the third quarter... 
From Business Wire News Releases
AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑01, an Investigational Gene Therapy for Fabry Disease
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has... 
From Business Wire News Releases
AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D Day
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will host a Virtual R&D Day for... 
From Business Wire News Releases
AVROBIO Appoints Dr. Gail Farfel to its Board of Directors
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Gail M. Farfel, Ph.D.,... 
From Business Wire News Releases
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory... 
From Business Wire News Releases
AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced an exclusive, worldwide license agreement... 
From Business Wire News Releases
AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has... 
From Business Wire News Releases
AVROBIO to Present at Two Upcoming Investor Conferences
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team... 
From Business Wire News Releases
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a... 
From Business Wire News Releases
AVROBIO to Present at Three Upcoming Investor Conferences
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team... 
From Business Wire News Releases
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory... 
From Business Wire News Releases
AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update
AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the second quarter... 
From Business Wire News Releases
AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO,... 
From Business Wire News Releases
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory... 
From Business Wire News Releases
AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the first patient has been dosed in... 
From Business Wire News Releases
AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Kim Raineri, as chief... 
From Business Wire News Releases
AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new preclinical data for AVR-RD-03 for... 
From Business Wire News Releases
AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new clinical data from its investigational... 
From Business Wire News Releases
AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended... 
From Business Wire News Releases
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory... 
From Business Wire News Releases
Magenta Therapeutics and AVROBIO Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
Magenta Therapeutics (Nasdaq: MGTA) and AVROBIO, Inc. (Nasdaq: AVRO) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel... 
From Business Wire News Releases
AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
AVROBIO, Inc. (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel... 
From Business Wire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account